在两个学术中心诊所对HIV感染的男男性行为者开展肛门癌筛查项目的五年评估
该研究为2018至2022年学术HIV诊所的回顾性病历审查,评估432名符合条件者中肛门细胞学筛查的5年接受度及HSIL检出率。结果显示仅50.7%至少筛查1次、26%筛查超过1次,肛门细胞学「不满意」率17.5%,按低阈值标准仅7.8%检出HSIL,若严格采用高阈值标准则无HRA或HSIL检出。
要点
- 符合条件者中仅50.7%至少接受1次筛查,26%接受超过1次。
- 年龄≥57岁和吸烟史与从未接受筛查呈负相关。
- 肛门细胞学「不满意」率17.5%,作为HRA转诊分诊试验敏感性低。
核心结论
- 筛查接受度随时间推移较差,尤其在年龄较大组中。
- 肛门细胞学作为HRA转诊的分诊试验表现不佳,「不满意」样本率高且检测HSIL敏感性低。
研究设计与样本
- 回顾性病历审查,2018至2022年,在学术HIV诊所开展。
- 评估符合条件人群(≥35岁HIV感染的男男性行为者)的5年细胞学筛查接受度。
- 基于当前低阈值标准及若采用高阈值标准,估计HSIL检出率。
主要发现
- 432名符合条件者中,219名(50.7%)至少接受1次筛查,113名(26%)接受超过1次,中位随访4年。
- 74名(17.1%)在随访期间至少1次肛门细胞学异常,其中56名(75.6%)接受了HRA。
- 年龄增长(≥57岁)和吸烟史与从未接受筛查呈负相关。
- 肛门细胞学(206名个体共365次检测)中17.5%为「不满意」,26.8%为任何异常细胞学(零例HSIL),触发HRA转诊。
- 仅34名个体(占筛查符合条件者的7.8%)曾被检出HSIL;严格采用高阈值标准转诊HRA将导致无HRA或HSIL检出。
关键数值与推荐
- 指南推荐≥35岁HIV感染的男男性行为者每年进行基于肛门细胞学的肛门鳞状细胞癌(SCCA)筛查。
- HRA推荐阈值取决于其可用性:可用性高时采用低阈值(任何异常细胞学),可用性低时采用高阈值(细胞学高级别鳞状上皮内病变[HSIL])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. METHODS: This was a retrospective chart review (2018-2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. RESULTS: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% "unsatisfactory" and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. CONCLUSIONS: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of "unsatisfactory" samples and low sensitivity for detecting HSIL.
引用
- Achhra AC, Chan E, Applebaum S, et al. Five-Year Evaluation of an Anal Cancer Screening Program in Men Who Have Sex With Men With HIV at 2 Academic Center Clinics. Clin Infect Dis. 2025. PMID: 39492696. doi:10.1093/cid/ciae541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。